Abbvie Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Abbvie Inc's ROI in the second quarter of 2026?
Abbvie Inc achieved a return on average invested assets (ROI) of 9.44 % in its second quarter of 2026, which is below Abbvie Inc's average return on investment, which stands at 11.07%.

ROI has improved compared to 6.15% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 104 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 1351, from total ROI ranking in the first quarter of 2026 at 1365.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	4.04 %	-8.6 %	-7.58 %	-4.16 %	-3.73 %
Y / Y Net Income Change TTM	67.49 %	-13.37 %	45.26 %	-18.45 %	174.65 %
Investment (TTM) in Millions	93,520	57,964	55,755	60,415	62,866
Return On Investment (TTM)	9.44 %	6.15 %	6.91 %	3.79 %	5.86 %
ABBV's Overall Ranking	# 1351	# 1365	# 1024	# 1470	# 1080
Seq. Investment Change TTM	12.93 %	-3.29 %	-3.16 %	-1.63 %	-0.79 %
Seq. Net Income Change TTM	73.47 %	-13.99 %	76.74 %	-36.49 %	-10.28 %
Net Income (TTM) in Millions	6,316	3,641	4,233	2,395	3,771

ABBV Company Profile >> Back to ABBV Roi Comparisons >> See Annual ABBV Return On Investment

Return On Investment ABBV's Ranking
Within:	No.
Industry	# 40
Sector	# 105
Overall	# 1351

Return On Investment Statistics
High	Average	Low
22.87 %	11.07 %	3.64 %
(Sep. 30, 2013)

Financial Statements
Abbvie Inc's II. Quarter Investments	$ 93,520 Millions	ABBV's Balance sheet
Abbvie Inc's II. Quarter Income	$ 3,616 Millions	Quarterly ABBV's Income Statement
ABBV's Income by Division		See ABBV's Income by Division

ABBV Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	55,755	63,743	62,628	76,455	108,354
Y / Y Investment Growth	-12.53 %	1.78 %	-18.09 %	-29.44 %	-8.39 %
Net Income in Millions	4,233	4,286	4,873	11,845	11,549
Y / Y Net Income Growth	-1.24 %	-12.05 %	-58.86 %	2.56 %	149.87 %
Annual Return On Investment	7.59 %	6.72 %	7.78 %	15.49 %	10.66 %

Annual Roi Comment

Despite deterioration in net income, company improved ROI to in the fiscal year 2025, company improved ROI to 7.59 % compare to previous year.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ABBV's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ABBV's Competitors
Subscribers only: Roi for Abbvie Inc's Suppliers
Subscribers only: Return On Investment for ABBV's Customers

Other Ratios
ABBV's Roa	ABBV's Inventory Turnover Ratio	ABBV's Growth Rates	ABBV's Dividend Statistics
	ABBV's Profitability Ratios	ABBV's Asset Turnover Ratio	ABBV's Dividend Growth
ABBV's Roe	ABBV's Valuation Ratios	ABBV's Financial Strength Ratios	ABBV's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector	ROI
Protalix Biotherapeutics inc	25.72 %
Pro dex Inc	24.29 %
Innoviva Inc	23.33 %
Electromed Inc	23.18 %
Zevra Therapeutics Inc	22.90 %
Iradimed Corporation	22.57 %
Alnylam Pharmaceuticals Inc	22.10 %
Eton Pharmaceuticals Inc	21.31 %
Dexcom Inc	20.98 %
Healthcare Services Group Inc	20.93 %
Arcutis Biotherapeutics Inc	20.77 %
Chemed Corporation	20.13 %
Resmed Inc	20.01 %
Halozyme Therapeutics Inc	19.99 %
Vertex Pharmaceuticals Inc	19.97 %
Agilent Technologies inc	19.84 %
Illumina Inc	19.61 %
Puma Biotechnology Inc	19.60 %
United Therapeutics Corporation	19.53 %
Zoetis Inc	19.44 %
Krystal Biotech Inc	19.16 %
Carlisle Companies Incorporated	18.88 %
Neurocrine Biosciences Inc	17.51 %
Intuitive Surgical Inc	17.11 %
Theravance Biopharma inc	17.10 %
Standard Biotools Inc	16.38 %
Inspire Medical Systems inc	16.34 %
Aveanna Healthcare Holdings Inc	16.32 %
Harmony Biosciences Holdings inc	15.85 %
Entera Bio Ltd	15.84 %

Date modified: 2026-09-12T18:09:50+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.